Heart valve replacement surgery

Past, present and future

Albert Starr, Cindy L. Fessler, Gary Grunkemeier, Guo Wei He

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

1. The present review covers the historical and present role of valvular surgery in treating heart disease and speculates what the future may be in this very important field of cardiac surgery. 2. One of the important elements of tissue valve replacement is durability and how to analyse the valves mathematically, so that the projected durability could be described from the observed period to an extended period. We found that the Weibull distribution is a very good mathematical method of describing the deterioration of tissue valves. 3. We also can see a very marked difference among different pericardial valves. The Carpentier-Edwards pericardial valve has tremendous durability compared with the previous generation of pericardial valves, namely the Ionescu-Shiley. 4. The incidence of structural valve deterioration varies according to the age of the patient at the time of implant. A very important feature to analyse in making a clinical decision with regard to the type of valve to implant is the age of the patient at the time of implantation, because this determines their long-term survival. 5. Another very important feature of valve replacement is the problem of valve thrombosis. This was the problem that we encountered in experimental animals and why it is so difficult to obtain a long-term survivor with mechanical valve replacement in dogs. Now, in humans, the incidence of thrombosis of these artificial valves is extremely low. 6. Another important feature of valve replacement is the incidence of late thromboembolism (TE). Differences in reports using the same valve are greater than differences between different prostheses and the average is approximately 1.5-2%/year incidence of TE. 7. We can conclude from this review that there has been significant progress in diminishing operative mortality and enhanced long-term survival following valve replacement over the past four decades. Increased durability of tissue valves has now become apparent, from the earliest application to the current time with glutaraldehyde-preserved pericardial valves. The late complication rates are approximately the same with all valve types, except that there is a dimunition in the possibility for valve thrombosis for tissue valves versus mechanical valves. Finally, anticoagulation continues to be required for mechanical valve replacement and we still require more durable tissue valves and freedom from anticoagulation for mechanical valves.

Original languageEnglish (US)
Pages (from-to)735-738
Number of pages4
JournalClinical and Experimental Pharmacology and Physiology
Volume29
Issue number8
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Heart Valves
Thrombosis
Thromboembolism
Incidence
Survival
Glutaral
Thoracic Surgery
Prostheses and Implants
Survivors
Heart Diseases
Dogs
Mortality

Keywords

  • Heart valve replacement
  • Structural valve deterioration
  • Thromboembolism
  • Valve thrombosis

ASJC Scopus subject areas

  • Physiology
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Heart valve replacement surgery : Past, present and future. / Starr, Albert; Fessler, Cindy L.; Grunkemeier, Gary; He, Guo Wei.

In: Clinical and Experimental Pharmacology and Physiology, Vol. 29, No. 8, 2002, p. 735-738.

Research output: Contribution to journalArticle

Starr, Albert ; Fessler, Cindy L. ; Grunkemeier, Gary ; He, Guo Wei. / Heart valve replacement surgery : Past, present and future. In: Clinical and Experimental Pharmacology and Physiology. 2002 ; Vol. 29, No. 8. pp. 735-738.
@article{23fe5a2c137a4ff5b87011550b86b5b2,
title = "Heart valve replacement surgery: Past, present and future",
abstract = "1. The present review covers the historical and present role of valvular surgery in treating heart disease and speculates what the future may be in this very important field of cardiac surgery. 2. One of the important elements of tissue valve replacement is durability and how to analyse the valves mathematically, so that the projected durability could be described from the observed period to an extended period. We found that the Weibull distribution is a very good mathematical method of describing the deterioration of tissue valves. 3. We also can see a very marked difference among different pericardial valves. The Carpentier-Edwards pericardial valve has tremendous durability compared with the previous generation of pericardial valves, namely the Ionescu-Shiley. 4. The incidence of structural valve deterioration varies according to the age of the patient at the time of implant. A very important feature to analyse in making a clinical decision with regard to the type of valve to implant is the age of the patient at the time of implantation, because this determines their long-term survival. 5. Another very important feature of valve replacement is the problem of valve thrombosis. This was the problem that we encountered in experimental animals and why it is so difficult to obtain a long-term survivor with mechanical valve replacement in dogs. Now, in humans, the incidence of thrombosis of these artificial valves is extremely low. 6. Another important feature of valve replacement is the incidence of late thromboembolism (TE). Differences in reports using the same valve are greater than differences between different prostheses and the average is approximately 1.5-2{\%}/year incidence of TE. 7. We can conclude from this review that there has been significant progress in diminishing operative mortality and enhanced long-term survival following valve replacement over the past four decades. Increased durability of tissue valves has now become apparent, from the earliest application to the current time with glutaraldehyde-preserved pericardial valves. The late complication rates are approximately the same with all valve types, except that there is a dimunition in the possibility for valve thrombosis for tissue valves versus mechanical valves. Finally, anticoagulation continues to be required for mechanical valve replacement and we still require more durable tissue valves and freedom from anticoagulation for mechanical valves.",
keywords = "Heart valve replacement, Structural valve deterioration, Thromboembolism, Valve thrombosis",
author = "Albert Starr and Fessler, {Cindy L.} and Gary Grunkemeier and He, {Guo Wei}",
year = "2002",
doi = "10.1046/j.1440-1681.1999.03710.x",
language = "English (US)",
volume = "29",
pages = "735--738",
journal = "Clinical and Experimental Pharmacology and Physiology",
issn = "0305-1870",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Heart valve replacement surgery

T2 - Past, present and future

AU - Starr, Albert

AU - Fessler, Cindy L.

AU - Grunkemeier, Gary

AU - He, Guo Wei

PY - 2002

Y1 - 2002

N2 - 1. The present review covers the historical and present role of valvular surgery in treating heart disease and speculates what the future may be in this very important field of cardiac surgery. 2. One of the important elements of tissue valve replacement is durability and how to analyse the valves mathematically, so that the projected durability could be described from the observed period to an extended period. We found that the Weibull distribution is a very good mathematical method of describing the deterioration of tissue valves. 3. We also can see a very marked difference among different pericardial valves. The Carpentier-Edwards pericardial valve has tremendous durability compared with the previous generation of pericardial valves, namely the Ionescu-Shiley. 4. The incidence of structural valve deterioration varies according to the age of the patient at the time of implant. A very important feature to analyse in making a clinical decision with regard to the type of valve to implant is the age of the patient at the time of implantation, because this determines their long-term survival. 5. Another very important feature of valve replacement is the problem of valve thrombosis. This was the problem that we encountered in experimental animals and why it is so difficult to obtain a long-term survivor with mechanical valve replacement in dogs. Now, in humans, the incidence of thrombosis of these artificial valves is extremely low. 6. Another important feature of valve replacement is the incidence of late thromboembolism (TE). Differences in reports using the same valve are greater than differences between different prostheses and the average is approximately 1.5-2%/year incidence of TE. 7. We can conclude from this review that there has been significant progress in diminishing operative mortality and enhanced long-term survival following valve replacement over the past four decades. Increased durability of tissue valves has now become apparent, from the earliest application to the current time with glutaraldehyde-preserved pericardial valves. The late complication rates are approximately the same with all valve types, except that there is a dimunition in the possibility for valve thrombosis for tissue valves versus mechanical valves. Finally, anticoagulation continues to be required for mechanical valve replacement and we still require more durable tissue valves and freedom from anticoagulation for mechanical valves.

AB - 1. The present review covers the historical and present role of valvular surgery in treating heart disease and speculates what the future may be in this very important field of cardiac surgery. 2. One of the important elements of tissue valve replacement is durability and how to analyse the valves mathematically, so that the projected durability could be described from the observed period to an extended period. We found that the Weibull distribution is a very good mathematical method of describing the deterioration of tissue valves. 3. We also can see a very marked difference among different pericardial valves. The Carpentier-Edwards pericardial valve has tremendous durability compared with the previous generation of pericardial valves, namely the Ionescu-Shiley. 4. The incidence of structural valve deterioration varies according to the age of the patient at the time of implant. A very important feature to analyse in making a clinical decision with regard to the type of valve to implant is the age of the patient at the time of implantation, because this determines their long-term survival. 5. Another very important feature of valve replacement is the problem of valve thrombosis. This was the problem that we encountered in experimental animals and why it is so difficult to obtain a long-term survivor with mechanical valve replacement in dogs. Now, in humans, the incidence of thrombosis of these artificial valves is extremely low. 6. Another important feature of valve replacement is the incidence of late thromboembolism (TE). Differences in reports using the same valve are greater than differences between different prostheses and the average is approximately 1.5-2%/year incidence of TE. 7. We can conclude from this review that there has been significant progress in diminishing operative mortality and enhanced long-term survival following valve replacement over the past four decades. Increased durability of tissue valves has now become apparent, from the earliest application to the current time with glutaraldehyde-preserved pericardial valves. The late complication rates are approximately the same with all valve types, except that there is a dimunition in the possibility for valve thrombosis for tissue valves versus mechanical valves. Finally, anticoagulation continues to be required for mechanical valve replacement and we still require more durable tissue valves and freedom from anticoagulation for mechanical valves.

KW - Heart valve replacement

KW - Structural valve deterioration

KW - Thromboembolism

KW - Valve thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0035988930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035988930&partnerID=8YFLogxK

U2 - 10.1046/j.1440-1681.1999.03710.x

DO - 10.1046/j.1440-1681.1999.03710.x

M3 - Article

VL - 29

SP - 735

EP - 738

JO - Clinical and Experimental Pharmacology and Physiology

JF - Clinical and Experimental Pharmacology and Physiology

SN - 0305-1870

IS - 8

ER -